A Deep Dive into the SGN-70 Vorsetuzumab represents a significant strategy in cancer, specifically targeting the CD22 protein expressed on malignant blood cells. Developed by the researchers, this antibody functions as an ADCC mechanism inducer, triggering the body's killing of affected cells. Investigat… Read More